Restylane SubQ, a non-animal stabilized hyaluronic acid gel for soft tissue augmentation of the mid- and lower face.
نویسندگان
چکیده
For people requiring large volumes to shape facial contours, add volume to a sunken midface, or correct asymmetry, the options today are limited. Fat injections for adding volume, solid implants for cheeks and chin enhancement, face lift and injectable permanent or semi-permanent products are some of the alternatives used. With the trend towards less invasive and nonpermanent alternatives to plastic surgery, the use of injectable filler materials for facial rejuvenation and correction of soft-tissue defects is becoming increasingly popular. These materials provide volume expansion within the dermis, thereby smoothing out overlying facial wrinkles and enhancing facial contours. Ease of application, minimal procedural discomfort, and rapid patient recovery make injectable fillers well suited for outpatient use. Ideally, a filler material should be biocompatible, nontoxic, nonimmunogenic, and nonmigratory. Several biomaterials have been developed, such as bovine collagen, autologous and allogeneic human collagen, autologous fat, fibroblasts, and hyaluronic acid. However, although they are largely biocompatible, reabsorption and lack of sustained cosmetic effect are major drawbacks. Non-animal stabilized hyaluronic acid (NASHA) offers a longer-lasting aesthetic effect than bovine collagen or avian hyaluronic acid in facial soft-tissue augmentation, and a potentially lower risk of inflammatory reactions. Restylane SubQ is a new NASHA product indicated for deep subcutaneous or supraperiostal injection to replace volume loss in facial adipose tissues and create more defined facial contours.
منابع مشابه
Transdermal injection of Restylane SubQ for aesthetic contouring of the cheeks, chin, and mandible.
Initial experience in transdermal administration of Restylane SubQ for augmentation of the cheek and chin suggests that the product is easy to administer via this route and that it provides a stable aesthetic result. Local adverse reactions are consistent with those expected of an alloplastic filler material and appear to be related to the injection procedure/site rather than to the product its...
متن کاملRandomized, double-blind comparison of the efficacy of two hyaluronic acid derivatives, restylane perlane and hylaform, in the treatment of nasolabial folds.
BACKGROUND Cross-linked hyaluronic acid gels may offer longer-lasting cosmetic correction and a lower risk of immunogenicity than other soft tissue augmentation agents. OBJECTIVE To compare the efficacy and safety of a non-animal-stabilized hyaluronic acid gel (Restylane Perlane, Q-Med, Uppsala, Sweden) with that of a hylan B gel (Hylaform, Genzyme Corp., Cambridge, MA, USA), a cross-linked h...
متن کاملSafety data of injectable nonanimal stabilized hyaluronic acid gel for soft tissue augmentation.
BACKGROUND Nonanimal hyaluronic acid gel was recently developed for soft tissue augmentation and volume expansion and has been shown to offer several advantages in comparison to other augmentation materials. There are rare reports of adverse events believed to be secondary to trace amounts of proteins in the hyaluronic acid raw material. OBJECTIVE To determine the safety profile of nonanimal ...
متن کاملThe Efficacy of Hyaluronic Acid in the Restoration of Soft Tissue Volume of the Lips and Lower 1/3 of the Face: The Evolution of the Injection Technique
Study Objective: To establish the safety and efficacy of small-gel particle hyaluronic acid (SGP-HA; Restylane, Medicis Aesthetics Inc., Scottsdale, AZ) for lip augmentation. Study Design: This was a Phase 3, prospective, open-label, evaluator-blinded, single-center pilot study of SGP-HA use in lip augmentation. The primary efficacy objectives were to investigate the efficacy of SGP-HA in lip a...
متن کاملHyaluronic acid gel ( Juvéderm™) preparations in the treatment of facial wrinkles and folds
Soft tissue augmentation with temporary dermal fillers is a continuously growing field, supported by the ongoing development and advances in technology and biocompatibility of the products marketed. The longer lasting, less immunogenic and thus more convenient hyaluronic acid (HA) fillers are encompassing by far the biggest share of the temporary dermal filler market. Since the approval of the ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Aesthetic surgery journal
دوره 26 1S شماره
صفحات -
تاریخ انتشار 2006